(Q37793831)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20877307%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

The Japanese experience with biologic therapies for rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20877307%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20877307%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Hideto Kameda

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20877307%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

English

0 references

publication date

28 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20877307%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20877307%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20877307%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20877307%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

644-652

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20877307%20AND%20SRC:MED&resulttype=core&format=json

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Treating rheumatoid arthritis to target: recommendations of an international task force

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J).

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

31 March 2020

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Serum indicators for the diagnosis of pneumocystis pneumonia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

The other side of TNF-targeted therapy of patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Effects of infliximab therapy on gene expression levels of tumor necrosis factor alpha, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

ADAMTS5 is a biomarker for prediction of response to infliximab in patients with rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Fcγ receptor type IIIA genotype and response to tumor necrosis factor α–blocking agents in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Genetic risk factors for infection in patients with early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.154

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

31 March 2020

1 reference

12 December 2020

Guidelines for the proper use of etanercept in Japan

1 reference

12 December 2020

Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis

1 reference

12 December 2020

A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis

1 reference

12 December 2020

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM)

1 reference

12 December 2020

Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study

1 reference

12 December 2020

Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis.

1 reference

12 December 2020

Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis

1 reference

12 December 2020

HLA-B27 and its subtypes in world populations

1 reference

12 December 2020

Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis

1 reference

12 December 2020

Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.

1 reference

12 December 2020